| Original language | English (US) |
|---|---|
| Pages (from-to) | 319-321 |
| Number of pages | 3 |
| Journal | JACC: Basic to Translational Science |
| Volume | 7 |
| Issue number | 3P2 |
| DOIs | |
| State | Published - Mar 2022 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Basic to Translational Science, Vol. 7, No. 3P2, 03.2022, p. 319-321.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Splanchnic Nerve Ablation for Volume Management in Heart Failure
AU - Fudim, Marat
AU - Engelman, Zoar J.
AU - Reddy, Vivek Y.
AU - Shah, Sanjiv J.
N1 - Funding Information: Dr Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), an American Heart Association Mario Family Award (20IPA35310955), Duke Chair’s Award, Translating Duke Health Award, Bayer, Bodyport, and BTG Specialty Pharmaceuticals, and receives consulting fees from Abbott, Audicor, Axon Therapies, Bodyguide, Bodyport, Boston Scientific, CVRx, Daxor, Edwards LifeSciences, Feldschuh Foundation, Fire1, Gradient, Intershunt, NXT Biomedical, Pharmacosmos, PreHealth, Splendo, Vironix, Viscardia, and Zoll. Dr Engelman consults for and owns stock in Axon Therapies. Dr Reddy serves as a consultant to and holds stock options in Axon Therapies and has other disclosures not related to this manuscript: Abbott (consultant), Ablacon (consultant, equity), Acutus Medical (consultant, equity), Affera (consultant, equity), Apama Medical (consultant, equity), APN Health (consultant, equity), Aquaheart (consultant, equity), Atacor (consultant, equity), Autonomix (consultant, equity), Backbeat (consultant, equity), BioSig (consultant, equity), Biosense-Webster (consultant), BioTel Heart (consultant), Biotronik (consultant), Boston Scientific (consultant), Cardiac Implants (consultant, equity), CardiaCare (consultant, equity), Cardiofocus (consultant), Cardionomic (consultant), CardioNXT/AFTx (consultant, equity), Circa Scientific (consultant, equity), CoreMap (consultant), Corvia Medical (consultant, equity), Dinova-Hangzhou DiNovA EP Technology (consultant, equity), East End Medical (consultant, equity), EBR (consultant), EPD (consultant, equity), Epix Therapeutics (consultant, equity), EpiEP (consultant, equity), Eximo (consultant, equity), Farapulse (consultant, equity), Fire1 (consultant), Gore & Associates (consultant), HRT (consultant, equity), Impulse Dynamics (consultant), Intershunt (consultant, equity), Javelin (consultant, equity), Kardium (consultant, equity), Keystone Heart (consultant, equity), LuxMed (consultant, equity), Manual Surgical Sciences (Equity), Medlumics (consultant, equity), Medtronic (consultant), Middlepeak (consultant, equity), Newpace (Equity), Nuvera (consultant, equity), Philips (consultant), Pulse Biosciences (consultant), Restore Medical (consultant, equity), Sirona Medical (consultant, equity), Surecor (Equity), Valcare (consultant, equity), and Vizaramed (Equity). Dr Shah has received research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer, and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. Funding Information: Dr Fudim was supported by the National Heart, Lung, and Blood Institute (K23HL151744), an American Heart Association Mario Family Award (20IPA35310955), Duke Chair's Award, Translating Duke Health Award, Bayer, Bodyport, and BTG Specialty Pharmaceuticals, and receives consulting fees from Abbott, Audicor, Axon Therapies, Bodyguide, Bodyport, Boston Scientific, CVRx, Daxor, Edwards LifeSciences, Feldschuh Foundation, Fire1, Gradient, Intershunt, NXT Biomedical, Pharmacosmos, PreHealth, Splendo, Vironix, Viscardia, and Zoll. Dr Engelman consults for and owns stock in Axon Therapies. Dr Reddy serves as a consultant to and holds stock options in Axon Therapies and has other disclosures not related to this manuscript: Abbott (consultant), Ablacon (consultant, equity), Acutus Medical (consultant, equity), Affera (consultant, equity), Apama Medical (consultant, equity), APN Health (consultant, equity), Aquaheart (consultant, equity), Atacor (consultant, equity), Autonomix (consultant, equity), Backbeat (consultant, equity), BioSig (consultant, equity), Biosense-Webster (consultant), BioTel Heart (consultant), Biotronik (consultant), Boston Scientific (consultant), Cardiac Implants (consultant, equity), CardiaCare (consultant, equity), Cardiofocus (consultant), Cardionomic (consultant), CardioNXT/AFTx (consultant, equity), Circa Scientific (consultant, equity), CoreMap (consultant), Corvia Medical (consultant, equity), Dinova-Hangzhou DiNovA EP Technology (consultant, equity), East End Medical (consultant, equity), EBR (consultant), EPD (consultant, equity), Epix Therapeutics (consultant, equity), EpiEP (consultant, equity), Eximo (consultant, equity), Farapulse (consultant, equity), Fire1 (consultant), Gore & Associates (consultant), HRT (consultant, equity), Impulse Dynamics (consultant), Intershunt (consultant, equity), Javelin (consultant, equity), Kardium (consultant, equity), Keystone Heart (consultant, equity), LuxMed (consultant, equity), Manual Surgical Sciences (Equity), Medlumics (consultant, equity), Medtronic (consultant), Middlepeak (consultant, equity), Newpace (Equity), Nuvera (consultant, equity), Philips (consultant), Pulse Biosciences (consultant), Restore Medical (consultant, equity), Sirona Medical (consultant, equity), Surecor (Equity), Valcare (consultant, equity), and Vizaramed (Equity). Dr Shah has received research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer, and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics.
PY - 2022/3
Y1 - 2022/3
UR - http://www.scopus.com/inward/record.url?scp=85126902798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126902798&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2022.02.005
DO - 10.1016/j.jacbts.2022.02.005
M3 - Article
C2 - 35411330
AN - SCOPUS:85126902798
SN - 2452-302X
VL - 7
SP - 319
EP - 321
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 3P2
ER -